Hepatitis B
Coverage of the 2016 AASLD Liver Meeting
- Details
- Category: Hepatitis B
- Published on Thursday, 02 February 2017 00:00
- Written by HIVandHepatitis.com
HIVandHepatitis.com coverage of the 2016 Liver Meeting, annual conference of the American Association for the Study of Liver Diseases, AASLD), November 11-15, 2016, in Boston.
Hepatitis C
- Glecaprevir/Pibrentasvir Effective for Hepatitis C Patients with Severe Kidney Disease
- Curing Hepatitis C May Help Reduce Kidney Disease Progression
- Real-World Studies Show 8 Weeks of Sofosbuvir/Ledipasvir Equals 12 Weeks for Many Patients
- Generic Sofosbuvir Underperforms in Real World, May Be Due to Suboptimal Regimens
- 6 Weeks of Sofosbuvir/Ledipasvir Cures Genotype 1 Acute Hepatitis C
- Non-Adherence Is Most Important Risk Factor for Sofosbuvir/Ledipasvir Failure
- Primary Care Providers Can Effectively Treat Patients with Hepatitis C
- Grazoprevir Triple Regimen Demonstrates High Cure Rates, Even for Hard-to-Treat Patients
- 8-Week Triple Combo Cures Most Patients with Genotype 1-6 Hepatitis C
- AbbVie Pangenotypic Combination Cures 98% or More Across HCV Genotypes
- AbbVie Pangenotypic Combination Cures Almost All Hard-to-Treat People with HCV Genotype 3
- U.S. Veterans Health System and Australia Show Potential for Rapid Elimination of Hepatitis C
- Real-World Responses to HCV Treatment Among U.S. Veterans Match Stellar Clinical Trial Results
- Grazoprevir/Elbasvir + Sofosbuvir Highly Effective for Hard-to-Treat Genotype 3 Hepatitis C Patients
- Birth Cohort Screening and Linkage to Hepatitis C Care Still Weak in U.S.
HIV/HCV Coinfection
- Hepatitis C Virus Infection Rising Among Gay Men in San Diego
- Sofosbuvir/Ledipasvir Effective for HIV/HCV Coinfected People in Real-World Cohorts
- HIV/HCV Coinfected People See Good Cure Rates in Real-World Clinical Practice in Madrid
Liver Disease Progression
- Liver Cirrhosis and Decompensation on the Rise Among People with Hepatitis C
- Curing Hepatitis C Reduces Liver-Related Complications and Death
- Is DAA Treatment for Hepatitis C Reducing the Need for Liver Transplants?
- Portal Hypertension Less Likely to Improve After HCV Treatment When Fibrosis Is Severe
- Liver Cancer Risk Reduced After Hepatitis C Treatment, But Vigilance Needed
Hepatitis B and D
- Is Better Treatment Improving Outcomes Among People with Hepatitis B?
- Lonafarnib Lowers Hepatitis Delta Levels with Acceptable Side Effects
- GS-4774 Therapeutic Vaccine Shows Little Efficacy in People with Hepatitis B
- Nucleic Acid Polymers Reduce HBsAg Levels and Improve Control of Hepatitis B Virus
- Tenofovir Alafenamide Approved for Hepatitis B, Works Well with Less Effect on Bones